{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:15:50Z","timestamp":1791090950949,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,5,24]],"date-time":"2010-05-24T00:00:00Z","timestamp":1274659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Therapy (RCT)\u2028Level of Evidence\u20031b<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To determine whether the efficacy and safety of a combination of tolterodine extended\u2010release (ER) plus \u03b1\u2010blocker treatment varies with high or low levels of serum prostate\u2010specific antigen (PSA) in men who have persistent overactive bladder (OAB) symptoms after any \u03b1\u2010blocker monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      Men aged \u226540 years were eligible if they reported \u22658 micturitions\/24\u2003h, including \u22651 urgency episode\/24\u2003h with or without urgency urinary incontinence (UUI), and at least some moderate bladder\u2010related problems at baseline despite receiving treatment with an \u03b1\u2010blocker for \u22651 month. Exclusion criteria included a postvoid residual urine volume (PVR) of \u2265200\u2003mL and history of acute urinary retention requiring catheterization. Subjects were randomly assigned to tolterodine\u2010ER 4\u2003mg or placebo for 12 weeks; all subjects continued their \u03b1\u2010blocker treatment throughout the study. Subjects completed 5\u2010day bladder diaries at baseline and week 12, in which they recorded all micturitions and rated the sensation associated with each micturition using the 5\u2010point Urinary Sensation Scale (USS). For this\n                      <jats:italic>post hoc<\/jats:italic>\n                      analysis, efficacy, safety, and tolerability data were stratified by the study median PSA concentration at baseline (1.41\u2003ng\/mL).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      In the tolterodine\u2010ER +\u03b1\u2010blocker and placebo +\u03b1\u2010blocker groups, 160 and 159 men, respectively, had PSA levels of &lt;1.41\u2003ng\/mL, and 166 and 160 men, respectively, had PSA levels of \u22651.41\u2003ng\/mL. Men with higher PSA levels were slightly older and had higher PVR at baseline compared with men with lower PSA levels. At week 12, improvements in daytime micturitions, 24\u2010h urgency episodes, and daytime urgency episodes were significantly greater with tolterodine\u2010ER +\u03b1\u2010blocker vs placebo +\u03b1\u2010blocker both in men with PSA levels of \u22651.41\u2003ng\/mL and those with PSA levels of &lt;1.41\u2003ng\/mL (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). Among men with PSA levels of &lt;1.41\u2003ng\/mL, improvements in 24\u2010h micturitions and frequency\u2010urgency sum (sum of USS ratings for all micturitions) were also significantly greater with tolterodine\u2010ER +\u03b1\u2010blocker vs placebo +\u03b1\u2010blocker (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). There were no significant treatment differences in change in UUI episodes in either PSA group (although only 19% of subjects reported UUI at baseline), nor in nocturnal micturitions or nocturnal urgency episodes. Among men with PSA levels of \u22651.41\u2003ng\/mL, there was a statistically significant increase in PVR (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.036) and decrease in maximum urinary flow rate (Q\n                      <jats:sub>max<\/jats:sub>\n                      ;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.038) with tolterodine\u2010ER +\u03b1\u2010blocker vs placebo +\u03b1\u2010blocker ; these changes were not considered clinically meaningful. There were no treatment differences for changes in PVR or Q\n                      <jats:sub>max<\/jats:sub>\n                      among men with PSA levels of &lt;1.41\u2003ng\/mL. One subject receiving tolterodine\u2010ER +\u03b1\u2010blocker (PSA concentration of \u22651.41\u2003ng\/mL) and two subjects receiving placebo +\u03b1\u2010blocker (one each in the PSA concentration subgroups of \u22651.41\u2003ng\/mL and &lt;1.41\u2003ng\/mL) had acute urinary retention requiring catheterization.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>In a 12\u2010week study, the addition of tolterodine\u2010ER to \u03b1\u2010blocker therapy improved key OAB symptoms and appeared to be well tolerated compared with placebo +\u03b1\u2010blocker in men with persistent OAB symptoms, regardless of subjects\u2019 prostate size as judged by serum PSA concentration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2010.09359.x","type":"journal-article","created":{"date-parts":[[2010,5,26]],"date-time":"2010-05-26T20:37:46Z","timestamp":1274906266000},"page":"1332-1338","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy and safety of tolterodine extended\u2010release in men with overactive bladder symptoms treated with an \u03b1\u2010blocker: effect of baseline prostate\u2010specific antigen concentration"],"prefix":"10.1111","volume":"106","author":[{"given":"Christopher R.","family":"Chapple","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sender","family":"Herschorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph T.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,5,24]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.02.018"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20251"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65982-4"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.02.017"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)63949-3"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10057"},{"key":"e_1_2_8_11_2","first-page":"379","article-title":"Overactive bladder: treatment options in primary care medicine","volume":"107","author":"Sussman DO.","year":"2007","journal-title":"J Am Osteopath Assoc"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.11.026"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000067541.73285.eb"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.19.2319"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.05039.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00483-0"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000181823.33224.a0"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.03.006"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-007-0212-5"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06068.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1002"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01625.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000173630.94559.fd"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20586"},{"key":"e_1_2_8_25_2","article-title":"Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies","author":"Herschorn S","year":"2009","journal-title":"Urology"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365590902836740"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.06.067"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00655-4"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67962-1"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00654-2"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01155-4"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(02)00210-5"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00708-1"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.05.042"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00029330-200703010-00004"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.06.051"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07205.x"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.03.027"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.032"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2010.09359.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2010.09359.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:17:33Z","timestamp":1761743853000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2010.09359.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,24]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1111\/j.1464-410X.2010.09359.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2010.09359.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,24]]},"assertion":[{"value":"2010-05-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}